Risk adapted post-transplant maintenance in multiple myeloma

References

• Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017 Feb 4;389(10068):519–527. DOI:10.1016/S0140-6736(16)31594-X. PubMed PMID: 28017406; PubMed Central PMCID: PMCPMC5546834. eng.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018 Feb;32(2):383–390. PubMed PMID: 28761118; eng.
   PubMed Web of Science ®Google Scholar
• Libby E, Garcia D, Quintana D, et al. Disease-specific survival for patients with multiple myeloma: significant improvements over time in all age groups. Leuk Lymphoma. 2014 Dec;55(12):2850–2857. PubMed PMID: 24588734; eng.
   PubMed Web of Science ®Google Scholar
• Hari P, Romanus D, Luptakova K, et al. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. J Geriatr Oncol. 2018 Mar;9(2):138–144. PubMed PMID: 29056336; eng.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia. 2009 Nov;23(11):1941–1956. . PubMed PMID: 19657360; PubMed Central PMCID: PMCPMC3686133. eng.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015 Sep 10;33(26):2863–2869. PubMed PMID: 26240224; PubMed Central PMCID: PMCPMC4846284. eng.
   PubMed Web of Science ®Google Scholar
• Mh B, Park CJ, Kim BH, et al. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma. Cytometry B Clin Cytom. 2018 May;94(3):493–499. PubMed PMID: 29220877; eng.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv52–iv61. PubMed PMID: 28453614; eng.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770–1781. PubMed PMID: 22571201; PubMed Central PMCID: PMCPMC3744390. eng.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431–e442. PubMed PMID: 28826616; PubMed Central PMCID: PMCPMC5718627. eng.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012 Aug 20;30(24):2946–2955. PubMed PMID: 22802322; eng.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Hofmeister CC, Rosenbaum CA, et al. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol. 2018 Jul;182(2):231–244. PubMed PMID: 29938772; PubMed Central PMCID: PMCPMC6055619. eng.
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Corso A, Mugge LO, et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017 Nov;31(11):2435–2442. PubMed PMID: 28373701; PubMed Central PMCID: PMCPMC5668494. eng.
   PubMed Web of Science ®Google Scholar
• Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002 May 1;99(9):3163–3168. PubMed PMID: 11964279; eng.
   PubMed Web of Science ®Google Scholar
• Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000 Nov;11(11):1427–1436. PubMed PMID: 11142483; eng.
   PubMed Web of Science ®Google Scholar
• The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001 Jun ;113(4): 1020–1034. PubMed PMID: 11442498; eng.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada clinicals trials group myeloma 10 trial. Blood. 2013 Feb 28;121(9):1517–1523. PubMed PMID: 23297129; PubMed Central PMCID: PMCPMC3587317. eng.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012 Jan 5;119(1):7–15. PubMed PMID: 22021371; eng.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9;354(10):1021–1030. PubMed PMID: 16525139; eng.
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009 Apr 10;27(11):1788–1793. PubMed PMID: 19273705; eng.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006 Nov 15;108(10):3289–3294. PubMed PMID: 16873668; eng.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113–1120. PubMed PMID: 19880501; eng.
   PubMed Web of Science ®Google Scholar
• Brinker BT, Waller EK, Leong T, et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer. 2006 May 15;106(10):2171–2180. PubMed PMID: 16598756; eng.
   PubMed Web of Science ®Google Scholar
• Gao M, Kong Y, Wang H, et al. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials. Tumour Biol. 2016 Aug;37(8):11081–11098. 10.1007/s13277-016-4963-8. PubMed PMID: 26906553; eng.
   PubMedGoogle Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1782–1791. PubMed PMID: 22571202; eng.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 Sep 4;371(10):895–905. PubMed PMID: 25184862; eng.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017 Oct 10;35(29):3279–3289. PubMed PMID: 28742454; PubMed Central PMCID: PMCPMC5652871. eng.
   PubMed Web of Science ®Google Scholar
• Jackson G, Davies FE, Pawlyn C, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130:436.
   Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017 Apr 6;376(14):1311–1320. PubMed PMID: 28379796; eng.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM. Blood Adv. 2018 Jul 10;2(13):1608–1615. PubMed PMID: 29986853; PubMed Central PMCID: PMCPMC6039656. eng.
   PubMed Web of Science ®Google Scholar
• Abonour R, Wagner L, Durie BGM, et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the connect(R) MM registry. Ann Hematol. 2018 Jul 29. 10.1007/s00277-018-3446-y. PubMed PMID: 30056582; eng.
   PubMed Web of Science ®Google Scholar
• Osman K, Chari A, Parekh SS, et al. Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma. Biology of Blood and Marrow Transplantation. 2018;24(3):S49-S50.
   Google Scholar
• Shah GL, Assal A, Hsu M, et al. Depth and timing of improvement of response for multiple myeloma patients on lenalidomide maintenance after autologous hematopoietic stem cell transplantation (auto HCT). Biology of Blood and Marrow Transplantation. 2017;23(3):S271-S272.
   Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the intergroupe francophone Du MyéLome (IFM) Krd phase II study. Blood. 2016;128:1142.
   Google Scholar
• Mian I, Milton DR, Shah N, et al. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15;122(24):3831–3837. PubMed PMID: 27680710; PubMed Central PMCID: PMCPMC5138119. eng.
   PubMed Web of Science ®Google Scholar
• Gay F, Jackson G, Rosinol L, et al. Maintenance treatment and survival in patients with myeloma: A systematic review and network meta-analysis. JAMA Oncol. 2018 Aug 9. PubMed PMID: 30098165; eng. DOI:10.1001/jamaoncol.2018.2961.
   Web of Science ®Google Scholar
• Scheid C, Sonneveld P, Schmidt-Wolf IG, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2014 Jan;99(1):148–154. PubMed PMID: 23996482; PubMed Central PMCID: PMCPMC4007933. eng.
   PubMed Web of Science ®Google Scholar
• Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012 Jan 26;119(4):940–948. PubMed PMID: 22160383; eng.
   PubMed Web of Science ®Google Scholar
• Huang J, Phillips S, Byrne M, et al. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant. 2018 Jun;53(6):701–707. 10.1038/s41409-018-0177-6. PubMed PMID: 29703965; eng.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Kumar SK, et al. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018 Mar;32(3):712–718. PubMed PMID: 28848227; eng.
   PubMed Web of Science ®Google Scholar
• Sivaraj D, Green MM, Li Z, et al. Outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):262–268. PubMed PMID: 27856369; eng.
   PubMed Web of Science ®Google Scholar
• Zimmerman T, Raje NS, Vij R, et al. Final results of a phase 2 trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Blood. 2016;128:675.
   Google Scholar
• Sborov DW, Benson DM, Williams N, et al. Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. Br J Haematol. 2015 Oct;171(1):74–83. PubMed PMID: 26058589; PubMed Central PMCID: PMCPMC4600596. eng.
   PubMed Web of Science ®Google Scholar
• Ibata S, Sato T, Kuroda H, et al. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma. Cancer Chemother Pharmacol. 2016 Nov;78(5):1041–1049. 10.1007/s00280-016-3163-y. PubMed PMID: 27738809; PubMed Central PMCID: PMCPMC5083756. eng.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014 Mar;28(3):690–693. PubMed PMID: 24220275; eng.
   PubMed Web of Science ®Google Scholar
• Nair B, van Rhee F, Shaughnessy JD Jr., et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010 May 27;115(21):4168–4173. PubMed PMID: 20124509; PubMed Central PMCID: PMCPMC2879104. eng.
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1617–1629. PubMed PMID: 26596670; eng.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017 Sep;31(9):1922–1927. PubMed PMID: 28111466; eng.
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012 Jul 5;120(1):9–19. PubMed PMID: 22498745; eng.
   PubMed Web of Science ®Google Scholar
• Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a nordic myeloma study group randomized phase 3 trial. Blood. 2013 Jun 6;121(23):4647–4654. PubMed PMID: 23616624; PubMed Central PMCID: PMCPMC3674665. eng.
   PubMed Web of Science ®Google Scholar
• Einsele H, Knop S, Vogel M, et al. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. Leukemia. 2017 Jun;31(6):1463–1466. PubMed PMID: 28293022; eng.
   PubMed Web of Science ®Google Scholar
• Jacobus SJ, Rajkumar SV, Weiss M, et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J. 2016 Jul 29;6(7):e448. PubMed PMID: 27471864; PubMed Central PMCID: PMCPMC5030380 received honoraria for consulting from Celgene. Dr Dreosti has received speaker honorarium from Janssen Pharmaceuticals and congress sponsorship from Janssen Pharmaceuticals. Dr Fonseca has received consulting fees from Celgene and Takeda. The remaining authors declare no conflict of interest. eng.
   PubMedGoogle Scholar
• Stadtmauer EA, Pasquini MC, Blackwell B, et al. Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). ASH. 2016; 128:LBA-1.
   Google Scholar
• NCCN guidelines. [cited 2018 Nov 16]. www.NCCN.org2018.
   Google Scholar
• Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transplant. 2018 Jul 9. PubMed PMID: 29988062; eng. DOI:10.1038/s41409-018-0264-8.
   Google Scholar
• [cited 2018 May]. www.msmart.org.
   Google Scholar
• Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2018 Dec 10. PubMed PMID: 30545780; eng. DOI:10.1016/s0140-6736(18)33003-4.
   Web of Science ®Google Scholar
• Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18(4):381–390. PubMed PMID: 23442307; PubMed Central PMCID: PMCPMC3639525. eng.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2015 Oct;2(10):e408–e416. PubMed PMID: 26686042; eng.
   PubMed Web of Science ®Google Scholar